Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficient interventions for those affected with mucosal or systemic manifestations. The British Society of Rheumatology has updated its 2017 guidelines, with wider evidence and
Read Article
With better endpoint and patient selection strategy over the last 4 years, many new therapies have met their endpoints/shown promising signal in the Phase 2 randomised controlled trials in Sjogren's disease (iscalimab, ianalumab, dazodalibep, and sequential therapy belimumab + rituximab). Since
Read Article
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Links:
Links:
Links:
Links:
Links:
Dr. Jack Cush reviews regulatory reports, news and novel journal articles - this week focusing on Sjogren's, ILD, Gout and Uveitis.
Read Article
Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficient interventions for those affected with mucosal or systemic manifestations.
The British Society of Rheumatology has updated its 2017 guidelines, with
Read Article
A prospective study from the Netherlands analyzed the comparative value of simultaneous labial and parotid salivary gland biopsies performed in patients with sicca complaints and suspected Sjogren's syndrome (SjD).
Researchers from the University Medical Center Groningen compared
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, including where you should sit in clinic and why you should worry about secondary Sjogren's in RA.
Read Article
A Swiss observational study has shown that rheumatoid arthritis (RA) patients with concomitant Sjögren’s disease (SjD) are more likely to have a severe RA phenotype, and be less responsive to treatment.
From a total of 5974 RA patients, there were 337 patients with concomitant SjD. All
Read Article
